DE69412073T2 - Xanthinderivate als adenosin-a1 rezeptor antagonisten - Google Patents

Xanthinderivate als adenosin-a1 rezeptor antagonisten

Info

Publication number
DE69412073T2
DE69412073T2 DE69412073T DE69412073T DE69412073T2 DE 69412073 T2 DE69412073 T2 DE 69412073T2 DE 69412073 T DE69412073 T DE 69412073T DE 69412073 T DE69412073 T DE 69412073T DE 69412073 T2 DE69412073 T2 DE 69412073T2
Authority
DE
Germany
Prior art keywords
adenosine
pct
receptor antagonists
xanthine derivatives
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69412073T
Other languages
English (en)
Other versions
DE69412073D1 (de
Inventor
Janice Hitchcock
Stephen Sorenson
Mark Dudley
Norton Peet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69412073D1 publication Critical patent/DE69412073D1/de
Publication of DE69412073T2 publication Critical patent/DE69412073T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69412073T 1993-02-26 1994-01-27 Xanthinderivate als adenosin-a1 rezeptor antagonisten Expired - Fee Related DE69412073T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2350193A 1993-02-26 1993-02-26
PCT/US1994/001009 WO1994019349A1 (en) 1993-02-26 1994-01-27 Xanthine derivatives as adenosine a1 receptor antagonists

Publications (2)

Publication Number Publication Date
DE69412073D1 DE69412073D1 (de) 1998-09-03
DE69412073T2 true DE69412073T2 (de) 1999-02-18

Family

ID=21815459

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69412073T Expired - Fee Related DE69412073T2 (de) 1993-02-26 1994-01-27 Xanthinderivate als adenosin-a1 rezeptor antagonisten

Country Status (19)

Country Link
US (1) US5840729A (de)
EP (1) EP0686155B1 (de)
JP (1) JPH08512281A (de)
KR (1) KR100315898B1 (de)
CN (1) CN1041418C (de)
AT (1) ATE169019T1 (de)
AU (1) AU680241B2 (de)
CA (1) CA2155130C (de)
DE (1) DE69412073T2 (de)
DK (1) DK0686155T3 (de)
ES (1) ES2120025T3 (de)
HU (1) HUT72677A (de)
IL (1) IL108750A (de)
MX (1) MX9401406A (de)
NO (1) NO311920B1 (de)
NZ (1) NZ262984A (de)
TW (1) TW261532B (de)
WO (1) WO1994019349A1 (de)
ZA (1) ZA941176B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303624B1 (en) * 1997-03-18 2001-10-16 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for hyperphosphatemia
BR9911612A (pt) 1998-06-02 2001-02-06 Osi Pharm Inc Composições de pirrolo[2,3d]pirimidina e seus usos
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
WO2003048120A2 (en) 2001-11-30 2003-06-12 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors
WO2003053366A2 (en) 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. Pyrimidine a2b selective antagonist compounds, their synthesis and use
US6875883B2 (en) * 2002-05-15 2005-04-05 Genzyme Corporation Synthesis of benzonitriles from substituted benzaldehyde
WO2004086047A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1)
EP1709966A4 (de) * 2003-12-09 2009-04-29 Prophylaktisches und/oder therapeutisches mittel für höhere gehirnfunktionsstörungen
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
JPH0455150A (ja) * 1990-06-22 1992-02-21 Takata Kk 助手席用エアバッグ装置
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5087827A (en) * 1991-02-11 1992-02-11 Tektronix, Inc. Variable voltage transition circuit
US5208240A (en) * 1991-03-12 1993-05-04 Merrell Dow Pharmaceuticals Inc. 8-substituted purines as selective adenosine receptor agents
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
HUT72677A (en) 1996-05-28
JPH08512281A (ja) 1996-12-24
TW261532B (de) 1995-11-01
CN1118599A (zh) 1996-03-13
ZA941176B (en) 1994-09-20
EP0686155A1 (de) 1995-12-13
CA2155130C (en) 1994-09-01
NO953353L (no) 1995-08-25
US5840729A (en) 1998-11-24
HU9502495D0 (en) 1995-10-30
ATE169019T1 (de) 1998-08-15
IL108750A (en) 2000-09-28
AU680241B2 (en) 1997-07-24
CN1041418C (zh) 1998-12-30
ES2120025T3 (es) 1998-10-16
WO1994019349A1 (en) 1994-09-01
NZ262984A (en) 1997-05-26
NO953353D0 (no) 1995-08-25
MX9401406A (es) 1994-08-31
IL108750A0 (en) 1994-05-30
KR100315898B1 (ko) 2002-02-28
EP0686155B1 (de) 1998-07-29
CA2155130A1 (en) 1994-09-01
NO311920B1 (no) 2002-02-18
AU6296894A (en) 1994-09-14
DK0686155T3 (da) 1999-02-01
DE69412073D1 (de) 1998-09-03

Similar Documents

Publication Publication Date Title
ATE188379T1 (de) Fibrinogenrezeptor-antagonisten
DE69622031D1 (de) INDOLDERIVATE ALS cGMP-PDE INHIBITOREN
ATE166650T1 (de) Spiroazacyclischderivate als substanz p antagonisten
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
FI960727A (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
ES2121193T3 (es) Derivados de bencimidazoles.
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
DE69412073D1 (de) Xanthinderivate als adenosin-a1 rezeptor antagonisten
TR199900501T2 (xx) Benzamin t�revleri ve bunlar�n ila� olarak kullan�m�.
ATE184008T1 (de) Pyrrolopyridinderivate als dopaminrezeptor liganden
DK0960111T3 (da) Morphinderivat med analgesisk aktivitet
DE69606777D1 (de) Naphthamidderivate von 3-beta-amino azabicyclooctan oder nonan als antipsychotische arzneimittel
PL311296A1 (en) Derivatives of benzo [f] quinoxalinodione, method of obtaining them and their application in therapeutic agents
FR2695641B1 (fr) (Amino-3 phényl)-1 éthanesulfonate d'hydroquinine optiquement actif, sa préparation et son utilisation.
ATE221068T1 (de) Anellierte beta-carboline

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee